U.S. pauses Eli Lilly’s trial of a coronavirus antibody treatment over safety concerns

U.S. pauses Eli Lilly’s trial of a coronavirus antibody treatment over safety concerns

Eli Lilly's late-stage trial of its leading monoclonal antibody treatment for the coronavirus has been paused by U.S. health regulators over potential safety concerns, the company confirmed to CNBC."Safety is of the upmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," a spokeswoman told CNBC.The trial is designed to test the safety and efficacy of a potential new treatment for Covid-19, namely different varieties of monoclonal antibody treatments. It's one of several ongoing trials, as part of the National Institute of Health's "Activ" program, designed to accelerate the development of vaccine treatments in partnership with the pharmaceutical industry. It is also backed by Operation Warp Speed, the Trump Administration's effort to